{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:18:30Z","timestamp":1793981910901,"version":"4.8.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105239","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:36:51Z","timestamp":1772498211000},"page":"105239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-681X","authenticated-orcid":false,"given":"Anita","family":"Sto\u017cek-Tutro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ma\u0142owicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Janiszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105239_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib2","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/bloodadvances.2024015417","article-title":"Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL\/SLL","volume":"9","author":"Allan","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105239_bib3","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 Study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/ejh.14072","article-title":"Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib\u2014a retrospective analysis on consecutive patients from a well-defined region","volume":"111","author":"Andersson","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib6","doi-asserted-by":"crossref","DOI":"10.7326\/ACPJC-2016-164-8-044","article-title":"Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia","volume":"164","author":"Aronson","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2026.105239_bib7","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105239_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105239_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11523-023-00988-0","article-title":"Results from a real-world multicenter analysis of 482 patients with chronic lymphocytic leukemia treated with ibrutinib: a look at racial differences","volume":"18","author":"Barrientos","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12885-022-09256-2","article-title":"Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia","volume":"22","author":"Bourrier","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105239_bib11","first-page":"124","article-title":"Ibrutinib for first-line treatment of older patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a 4-year experience from the resonate-2 study","author":"Burger","year":"2018","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2026.105239_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105239_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102307","article-title":"Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY","author":"Chatzikonstantinou","year":"2023","journal-title":"eClinicalMedicine 65 102307"},{"key":"10.1016\/j.critrevonc.2026.105239_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251397071","article-title":"Global burden of chronic Lymphocytic Leukemia From 1990 to 2021","volume":"32","author":"Chen","year":"2025","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2026.105239_bib15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00277-024-05666-3","article-title":"Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study","volume":"104","author":"Dartigeas","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s44228-022-00015-5","article-title":"FIRE study: real-world effectiveness and safety of ibrutinib in clinical practice in patients with CLL and MCL","volume":"4","author":"Dartigeas","year":"2022","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.critrevonc.2026.105239_bib17","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.4294","article-title":"Efficacy and safety of obinutuzumab\u2013chlorambucil combination in the frontline treatment of elderly patients with chronic lymphocytic leukemia and comorbidities","author":"D\u0142ugosz-Donecka","year":"2018","journal-title":"Pol. Arch. Intern. Med. 128 421426"},{"key":"10.1016\/j.critrevonc.2026.105239_bib18","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia\u2606","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib19","unstructured":"EMA, 2014. Assessment report - Gazyvaro [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/gazyvaro-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2026.105239_bib20","unstructured":"EMA, 2020. Assessment report - Calquence [WWW Document]. URL \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/calquence-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2026.105239_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic Lymphocytic Leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2026.105239_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.17475","article-title":"A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)","volume":"194","author":"Eyre","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib23","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105239_bib24","first-page":"1","article-title":"Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia\/small lymphocytic lymphoma: an analysis of Veterans Health Administration data","volume":"3","author":"Fitzgerald","year":"2025","journal-title":"J. Manag Care Spec. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105239_bib25","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10428194.2021.1876863","article-title":"Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System","volume":"62","author":"Frei","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105239_bib26","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.287799","article-title":"Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice","author":"Frustaci","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105239_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ejh.14186","article-title":"Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: results from the German multicentre REALITY study","volume":"112","author":"Gerhardt","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjh.19613","article-title":"Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia","volume":"205","author":"Ghosh","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib29","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.clml.2024.05.009","volume":"24","author":"Ghosh","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2026.105239_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100022","article-title":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL\/SLL: a real-world analysis using target trial emulation","volume":"1","author":"Ghosh","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105239_bib31","article-title":"Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study","volume":"30","author":"Goede","year":"2018","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2026.105239_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105239_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25766","article-title":"Frontline treatment with the combination obinutuzumab \u00b1 chlorambucil for chronic lymphocytic leukemia outside clinical trials: results of a multinational, multicenter study by ERIC and the Israeli CLL study group","volume":"95","author":"Herishanu","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jha2.174","article-title":"Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK","volume":"2","author":"Hillmen","year":"2021","journal-title":"eJHaem"},{"key":"10.1016\/j.critrevonc.2026.105239_bib35","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic Lymphocytic Leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib36","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.18553\/jmcp.2020.20095","article-title":"Time to next treatment, health care resource utilization, and costs associated with ibrutinib use among U.S. Veterans with chronic lymphocytic leukemia\/small Lymphocytic Lymphoma: A Real-World Retrospective Analysis","volume":"26","author":"Huang","year":"2020","journal-title":"JMCP"},{"key":"10.1016\/j.critrevonc.2026.105239_bib37","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic Lymphocytic Leukemia by Risk Status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105239_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106335","article-title":"Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada","volume":"91","author":"Huang","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2026.105239_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5603\/ahp.97472","article-title":"Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists, and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2023","volume":"54","author":"Hus","year":"2023","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70033","article-title":"Acalabrutinib in high-risk chronic lymphocytic Leukaemia na\u00efve patients: an italian multicenter retrospective observational real-life experience","volume":"43","author":"Innocenti","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon-2023-0436","article-title":"Time to next treatment in patients with chronic lymphocytic Leukemia initiating first-line ibrutinib or acalabrutinib","volume":"20","author":"Jacobs","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s44228-022-00020-8","article-title":"Effectiveness and safety of ibrutinib for chronic lymphocytic leukemia in routine clinical practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study","volume":"4","author":"Janssens","year":"2022","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.critrevonc.2026.105239_bib43","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s12325-020-01350-w","article-title":"Real-world treatment patterns, adverse events, resource use, and costs among commercially insured, younger patients with chronic lymphocytic leukemia in the USA: A Retrospective Cohort Study","volume":"37","author":"Kabadi","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105239_bib44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/10428194.2023.2199340","article-title":"Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada","volume":"64","author":"Khelifi","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105239_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40801-022-00332-4","article-title":"Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic Lymphocytic Leukemia and small lymphocytic lymphoma","volume":"10","author":"Lee","year":"2023","journal-title":"Drugs Real. World Outcomes"},{"key":"10.1016\/j.critrevonc.2026.105239_bib46","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1002\/ajh.26779","article-title":"Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: a retrospective multicenter \u201cReal-World\u201d study","volume":"98","author":"Levi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib47","article-title":"Comparative safety of different first-line treatments for chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and network meta-analysis","author":"Liu","year":"2025","journal-title":"Ann. Hematol. 104 134"},{"key":"10.1016\/j.critrevonc.2026.105239_bib48","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3390\/cancers15164047","article-title":"Real-world evidence on the clinical characteristics and management of patients with chronic lymphocytic leukemia in spain using natural language processing: the SRealCLL Study","volume":"15","author":"Loscertales","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105239_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.27519","article-title":"Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia\/small lymphocytic lymphoma: a multicenter, real-world study in China","volume":"100","author":"Luo","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib50","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.3390\/cancers17142302","article-title":"Efficacy, toxicity and effect of pretreatment cardiologic consultation on outcomes of ibrutinib therapy for chronic lymphocytic Leukemia-A KroHem study","volume":"17","author":"Mandac Smoljanovi\u0107","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105239_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3249","article-title":"Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: a retrospective real-life multicenter Italian cohort","volume":"42","author":"Martino","year":"2024","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"haematol"},{"key":"10.1016\/j.critrevonc.2026.105239_bib53","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.25261","article-title":"Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial","volume":"93","author":"Mato","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib54","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3324\/haematol.2021.280376","article-title":"A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib","volume":"107","author":"Mato","year":"2022","journal-title":"haematol"},{"key":"10.1016\/j.critrevonc.2026.105239_bib55","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/cancers16061228","article-title":"Real-World outcome of treatment with single-agent ibrutinib in italian patients with chronic Lymphocytic Leukemia: final results of the EVIdeNCE Study","volume":"16","author":"Mauro","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105239_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.15386\/mpr-2800","article-title":"Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience","volume":"98","author":"Mesaros","year":"2025","journal-title":"Med Pharm. Rep."},{"key":"10.1016\/j.critrevonc.2026.105239_bib57","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth. 18 2127"},{"key":"10.1016\/j.critrevonc.2026.105239_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-024-03875-0","article-title":"Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study","volume":"121","author":"Muta","year":"2025","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib59","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/j.clml.2022.07.004","article-title":"Real-world persistence and time to next treatment with ibrutinib in patients with chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma including patients at high risk for atrial fibrillation or stroke","volume":"22","author":"Narezkina","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2026.105239_bib60","unstructured":"NCCN Clinical Practice Guidelines in Oncology, 2025. Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma v2 2025."},{"key":"10.1016\/j.critrevonc.2026.105239_bib61","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"key":"10.1016\/j.critrevonc.2026.105239_bib62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hon.2744","article-title":"Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: the GO-CLLEAR Study by the Czech CLL Study Group","volume":"38","author":"Panovsk\u00e1","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib63","article-title":"Real-world analysis of patients with CLL treated with ibrutinib: a retrospective analysis of Brazilian Registry of CLL","volume":"1","author":"Pfister","year":"2025","journal-title":"Blood Glob. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clml.2020.02.001","article-title":"Ibrutinib-associated Arthralgias\/Myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes","volume":"20","author":"Rhodes","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2026.105239_bib65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-023-00865-z","article-title":"Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency","volume":"13","author":"Rigolin","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105239_bib66","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/cancers17050799","article-title":"Real-World effectiveness of frontline treatments among patients with chronic lymphocytic leukemia: results from ConcertAI","volume":"17","author":"Roeker","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105239_bib67","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia","volume":"7","author":"Roeker","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105239_bib68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ajh.27639","article-title":"BTK Inhibitors versus venetoclax as first- or second-line therapy in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a real-world evidence study","volume":"100","author":"Roeker","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib69","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.3390\/curroncol28060408","article-title":"Examining treatment patterns and real-world outcomes in chronic lymphocytic Leukemia using administrative data in ontario","volume":"28","author":"Seung","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hon.3163_154","article-title":"Zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (pts) with treatment-na\u00efve (TN) CLL\/SLL: extended follow-up of the SEQUOIA study","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib71","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105239_bib72","unstructured":"Sto\u017cek-Tutro, A., Kawalec, P., 2024. PROSPERO - Protocol [WWW Document]. URL \u3008https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=549185\u3009."},{"key":"10.1016\/j.critrevonc.2026.105239_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104428","article-title":"Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis","volume":"201","author":"Sto\u017cek-Tutro","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib74","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.clinthera.2025.01.009","article-title":"Efficacy and safety of first-line targeted therapies in physically fit patients with chronic Lymphocytic Leukemia: a Systematic Review and Network Meta-analysis","volume":"47","author":"Sto\u017cek-Tutro","year":"2025","journal-title":"Clin. Ther."},{"key":"10.1016\/j.critrevonc.2026.105239_bib75","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib76","first-page":"1746","article-title":"Prolonged improvement in patient-reported outcomes (PROs) and well-being in older patients with treatment-naive (TN) chronic lymphocytic leukemia treated with ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study","volume":"130","author":"Tedeschi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105239_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/BLCTT.S262592","article-title":"The impact of age on survival in CLL patients receiving ibrutinib as initial therapy","volume":"10","author":"Ujjani","year":"2020","journal-title":"BLCTT"},{"key":"10.1016\/j.critrevonc.2026.105239_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033413","article-title":"Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study","volume":"12","author":"Visentin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib79","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1002\/ajh.26437","article-title":"Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: a real-life campus CLL study","volume":"97","author":"Visentin","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105239_bib80","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1007\/s12325-025-03344-y","article-title":"Real-world outcomes with orelabrutinib in patients with chronic lymphocytic Leukemia\/small Lymphocytic Lymphoma: a retrospective study","volume":"42","author":"Wang","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105239_bib81","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djae245","article-title":"Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis","volume":"117","author":"Wen","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105239_bib82","unstructured":"WHO, 2019. International Statistical Classification of Diseases and Related Health Problems 10th Revision [WWW Document]. URL https:\/\/icd.who.int\/browse10\/2019\/en (accessed 5.6.25)."},{"key":"10.1016\/j.critrevonc.2026.105239_bib83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2021.2021102","article-title":"Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea","volume":"56","author":"Yi","year":"2021","journal-title":"Blood Res."},{"key":"10.1016\/j.critrevonc.2026.105239_bib84","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/10428194.2025.2535693","article-title":"Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL \u2013 real-life data analysis of the Polish Adult leukemia group","volume":"66","author":"Zielonka","year":"2025","journal-title":"Leuk. & Lymphoma"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:56:39Z","timestamp":1775908599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":84,"alternative-id":["S1040842826001265"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105239","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105239"}}